Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression

医学 肾功能 肾脏疾病 临床终点 内科学 临床试验 安慰剂 泌尿科 病理 替代医学
作者
Hiddo J.L. Heerspink,Niels Jongs,Patrick Schloemer,Dustin J. Little,Meike Brinker,Christoph Tasto,Martin Karpefors,David C. Wheeler,George L. Bakris,Vlado Perkovic,Richard Nkulikiyinka,Jérôme Rossert,Samvel B. Gasparyan
出处
期刊:Journal of The American Society of Nephrology 卷期号:34 (12): 2025-2038 被引量:8
标识
DOI:10.1681/asn.0000000000000243
摘要

Significance Statement The established composite kidney end point in clinical trials combines clinical events with sustained large changes in GFR but does not weigh the relative clinical importance of the end point components. By contrast, a hierarchical composite end point (HCE) accounts for the clinical importance of the end point components. The authors developed and validated a kidney HCE that combines clinical kidney outcomes with longitudinal GFR changes (GFR slope). They demonstrate that in seven major placebo-controlled kidney outcome trials with different medications, treatment effect estimates on the HCE were consistently in similar directions and of similar magnitudes compared with treatment effects on the established kidney end point. The HCE's prioritization of clinical outcomes and ability to combine dichotomous outcomes with GFR slope make it an attractive alternative to the established kidney end point. Background The established composite kidney end point in clinical trials combines clinical events with sustained large changes in GFR. However, the statistical method does not weigh the relative clinical importance of the end point components. A HCE accounts for the clinical importance of the end point components and enables combining dichotomous outcomes with continuous measures. Methods We developed and validated a new HCE for kidney disease progression, performing post hoc analyses of seven major Phase 3 placebo-controlled trials that assessed the effects of canagliflozin, dapagliflozin, finerenone, atrasentan, losartan, irbesartan, and aliskiren in patients with CKD. We calculated the win odds (WOs) for treatment effects on a kidney HCE, defined as a hierarchical composite of all-cause mortality; kidney failure; sustained 57%, 50%, and 40% GFR declines from baseline; and GFR slope. The WO describes the odds of a more favorable outcome for receiving the active compared with the control. We compared the WO with the hazard ratio (HR) of the primary kidney outcome of the original trials. Results In all trials, treatment effects calculated with the WO reflected a similar direction and magnitude of the treatment effect compared with the HR. Clinical trials incorporating the HCE would achieve increased statistical power compared with the established composite end point at equivalent sample sizes. Conclusions In seven major kidney clinical trials, the WO and HR provided similar direction of treatment effect estimates with smaller HRs associated with larger WOs. The prioritization of clinical outcomes and inclusion of broader composite end points makes the HCE an attractive alternative to the established kidney end point.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
121314wld完成签到,获得积分10
刚刚
wjx发布了新的文献求助10
1秒前
weifeng完成签到,获得积分10
1秒前
叁月完成签到,获得积分10
1秒前
1秒前
2秒前
我淦完成签到 ,获得积分10
2秒前
2秒前
2秒前
2549360318完成签到,获得积分10
2秒前
2秒前
2秒前
hang发布了新的文献求助10
3秒前
4秒前
dwct发布了新的文献求助10
4秒前
weifeng发布了新的文献求助10
4秒前
4秒前
lubo完成签到,获得积分10
4秒前
4秒前
爰采唐矣发布了新的文献求助10
4秒前
5秒前
5秒前
善学以致用应助小芭乐采纳,获得10
5秒前
拂晓发布了新的文献求助10
5秒前
SciGPT应助feihua采纳,获得10
6秒前
6秒前
6秒前
dongdong发布了新的文献求助10
7秒前
7秒前
sdl发布了新的文献求助10
7秒前
7秒前
沉静丹寒发布了新的文献求助10
8秒前
泽丶完成签到,获得积分10
8秒前
AI_S发布了新的文献求助10
8秒前
情怀应助周常通采纳,获得10
9秒前
知栀完成签到 ,获得积分10
10秒前
lubo发布了新的文献求助10
10秒前
10秒前
SUN发布了新的文献求助10
10秒前
10秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974943
求助须知:如何正确求助?哪些是违规求助? 3519467
关于积分的说明 11198482
捐赠科研通 3255728
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877261
科研通“疑难数据库(出版商)”最低求助积分说明 806224